Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II heterologous prime-boost H5N1 AS03B vaccine study in children 6 to 35 months
2011-004734-33Phase 2
- Sponsor
- GSK
- Start
- Apr 2012
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of H5N1 A/Indonesia/05/2005 + AS03B and H5N1 A/turkey/Turkey/1/2005 with AS03B in Influenza A infection, sponsored by GSK. Primary endpoints: Primary immunogenicity endpoint and CHMP criteria after booster.
02
Drugs
H5N1 A/Indonesia/05/2005 + AS03BH5N1 A/turkey/Turkey/1/2005 with AS03B
03
Conditions
Influenza A infection
Beyond the preview
Go deeper on 2011-004734-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004734-33.